雷帕霉素洗脱支架在血小板高度活化状态冠状动脉介入治疗的疗效评价  

Evaluation of the effect of sirolimus-eluting stent on coronary artery disease with platelet hyper-activation

作　　者：张庆成[1] 张向峰[1] 汪承炜[1] 毕春晖[1] 

机构地区：[1]武警上海总队医院心血管内科,上海市201103

出　　处：《中华实用诊断与治疗杂志》2009年第3期253-255,共3页Journal of Chinese Practical Diagnosis and Therapy

摘　　要：目的:评价雷帕霉素药物洗脱支架治疗冠心病并血小板高度活化状态冠状动脉狭窄的疗效。方法:回顾202例冠心病患者行冠状动脉内支架介入治疗,其中131例为冠心病并血小板高度活化状态,采用雷帕霉素药物洗脱支架治疗62例,采用普通支架治疗69例;71例为冠心病不伴血小板高度活化状态,均为雷帕霉素药物洗脱支架治疗。结果:随访12个月,冠心病并血小板高度活化状态雷帕霉素药物洗脱支架治疗组,心脏事件发生率8.06%,普通支架治疗组心脏事件发生率10.14%,2组比较差异有统计学意义(P<0.01)。血小板高度活化状态冠状动脉再狭窄率比较,雷帕霉素药物洗脱支架治疗组11.29%,普通支架治疗组15.94%,2组比较差异有统计学意义(P<0.01)。结论:雷帕霉素药物洗脱支架能有效防止血小板高度活化状态冠状动脉病变新生内膜增殖和再狭窄,提高冠状动脉支架术的成功率,降低心脏事件发生率。Objective To evaluate the effect of sirolimus-eluting stent on coronary stenosis in coronary artery disease with platelet hyper-activation. Methods Among 202 coronary artery disease patients undergoing percutaneous coronary intervention, 131 patients were associated with platelet hyper-aetivation. Of these patients, sirolimus-eluting stent was applied in 62 cases, and bare metal stent was applied in 69 cases. Another 71 patients with non-platelet hyper-activation accepted sirolimus-eluting stent. Results During 12 months＇ follow-up survey, the occurrence of major adverse cardiac events was 8.06% in platelet hyper-activation patients who accepted sirolimus-eluting stent 10.04% in the patients who accepted bare metal stent （P〈0.01）. Coronary restenosis occurred in 11. 290,/00 in sirolimus-eluting stents group and 15. 94% in bare metal stent group respectively（P〈 0.01）. Conolusion The sirolimus-eluting stents could effectively prevent the recurrent coronary vessel restenosis induced by the proliferation of intima. Implantation of sirolimus-eluting stent may reduce the major adverse cardiac events and the frequency of repeated intervention in coronary artery disease patients associated with platelet hyper-activation.

关 键 词：冠状动脉疾病 支架 血小板 活化状态 

分 类 号：R541.4[医药卫生—心血管疾病]